Clinical Trial

Honeycomb: Evaluation of Radiprodil in Children with GRIN-related Disorder

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Study RAD-GRIN-101 is a phase 1B trial to assess safety, tolerability, PK, and potential efficacy of radiprodil for the treatment of GRIN-related disorder in children with a Gain-of-Function (GoF) genetic variant. The study is open-label, so all participants will be treated with radiprodil. Subjects' participation in the study is expected to last up to six months in Part A. After the end of part A, all participants who are still eligible can choose to continue to receive radiprodil as part of an open-label long-term treatment period (Part B).
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-04-05; most recent amendment 2024-11-13.
Status change: Recruiting → Active, Not Recruiting 2024-11-13
Trial Details
NCT Number NCT05818943
Lead Sponsor GRIN Therapeutics, Inc.
Conditions GRIN-related Disorders
Enrollment 24 participants
Start Date 2023-03-07
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2024-11-15